Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 14.69 -3.36% -0.51
IRWD closed down 3.88 percent on Tuesday, February 19, 2019, on 1.13 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical IRWD trend table...

Date Alert Name Type % Chg
Feb 19 Upper Bollinger Band Walk Strength 0.55%
Feb 19 Inside Day Range Contraction 0.55%
Feb 19 Upper Bollinger Band Touch Strength 0.55%
Feb 15 180 Bullish Setup Bullish Swing Setup -3.36%
Feb 15 Stochastic Reached Overbought Strength -3.36%
Feb 15 Upper Bollinger Band Walk Strength -3.36%
Feb 15 Above Upper BB Strength -3.36%
Feb 15 Overbought Stochastic Strength -3.36%
Feb 15 Upper Bollinger Band Touch Strength -3.36%
Feb 14 Jack-in-the-Box Bullish Bullish Swing Setup 5.53%

Older signals for IRWD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Medical Specialties Cardiovascular Diseases Central Nervous System Disorders Gastroenterology Peptides European Union Irritable Bowel Syndrome Gastrointestinal Diseases Digestive Diseases Gastrointestinal Disorders Constipation Functional Constipation Human Therapeutic Products Ironwood Pharmaceuticals Linaclotide
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.2
52 Week Low 9.07
Average Volume 1,642,148
200-Day Moving Average 16.1159
50-Day Moving Average 12.2448
20-Day Moving Average 13.5
10-Day Moving Average 14.016
Average True Range 0.7798
ADX 28.42
+DI 25.1504
-DI 9.7286
Chandelier Exit (Long, 3 ATRs ) 12.8706
Chandelier Exit (Short, 3 ATRs ) 14.2694
Upper Bollinger Band 14.9845
Lower Bollinger Band 12.0155
Percent B (%b) 0.87
BandWidth 21.992593
MACD Line 0.5974
MACD Signal Line 0.5068
MACD Histogram 0.0906
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -14.91
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.63
Resistance 3 (R3) 15.70 15.44 15.46
Resistance 2 (R2) 15.44 15.18 15.40 15.40
Resistance 1 (R1) 15.02 15.02 14.89 14.95 15.35
Pivot Point 14.76 14.76 14.69 14.72 14.76
Support 1 (S1) 14.34 14.50 14.21 14.27 13.87
Support 2 (S2) 14.08 14.34 14.04 13.82
Support 3 (S3) 13.66 14.08 13.76
Support 4 (S4) 13.59